# The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.

> **NCT04065282** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 36 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04065282
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-06
- **Primary completion:** 2020-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04065282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04065282, "The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04065282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*